Literature DB >> 21236697

The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma.

Jahangir Abdi1, Ferdi Engels, Johan Garssen, Frank Redegeld.   

Abstract

Toll-like receptors are critical structures in sensing the invading pathogens via conserved moieties termed pathogen associated molecular patterns and in directing the innate and adaptive immune responses. Studies have shown that Toll-like receptors are not limited to normal immune cells but are expressed on tumour cells as well, including those of lymphoid neoplasms particularly B-cell malignancies, multiple myeloma and chronic lymphocytic leukemia. Neoplastic plasma cells in multiple myeloma usually show a different pattern of Toll-like receptor expression compared to normal B cells. These receptors on multiple myeloma cells, have been indicated to have a role in their proliferation, differentiation and survival, probably through induction of autocrine IL-6 secretion, and in their immunomodulatory functions. Moreover, it is speculated that these molecules may contribute to osteolytic lesions through activation of osteoclasts, and to angiogenesis through induction of pro-angiogenic factors. Knowledge on Toll-like receptor signalling in the biology of malignant plasma cells or their cellular microenvironment may give new insights into pathogenesis of multiple myeloma and may open new avenues for the therapy of this disease.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21236697     DOI: 10.1016/j.critrevonc.2010.12.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

Review 1.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

2.  Clinical significance of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in acute cerebral hemorrhage with gastrointestinal hemorrhage, and logistic regression analysis of risk factors.

Authors:  Yu Zou; Wei Zhang; Chuanjun Huang; Yangqing Zhu
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

3.  TLR2-activated B cells are phenotypically similar to the abnormal circulating B cells seen preceding the diagnosis of AIDS-related NHL diagnosis.

Authors:  Yu Guo; Basile Siewe; Marta Epeldegui; Roger Detels; Alan L Landay; Otoniel Martínez-Maza
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

4.  Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation.

Authors:  Mark G J de Boer; Hetty Jolink; Constantijn J M Halkes; Pim L J van der Heiden; Dennis Kremer; J H Frederik Falkenburg; Esther van de Vosse; Jaap T van Dissel
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

5.  Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.

Authors:  Jahangir Abdi; Tuna Mutis; Johan Garssen; Frank A Redegeld
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

6.  Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.

Authors:  Woodrow J Coker; Ashley Jeter; Henning Schade; Yubin Kang
Journal:  Biomark Res       Date:  2013-02-04

7.  Characterization of the Toll-like receptor expression profile in human multiple myeloma cells.

Authors:  Jahangir Abdi; Tuna Mutis; Johan Garssen; Frank Redegeld
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

8.  TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling.

Authors:  Ying Chen; Jing Zhao; Dengzhe Li; Jinxia Hao; Pengcheng He; Huaiyu Wang; Mei Zhang
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.